Physician profile
Anne Mani
NPI 1487852729
$1,993.57
in general payments reported to CMS, 2019-2025
18 companies · $315 in 2025
The $315 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.91 · 2021: $509 · 2022: $516 · 2023: $264 · 2024: $375 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $527.91 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $278.74 | 2021-2025 | |
| Abbott Laboratories | $179.08 | 2019-2024 | Amplatzer Amulet, Mitraclip, Epic |
| Atricure, INC. | $147.77 | 2021 | |
| Merck Sharp & Dohme LLC | $131.03 | 2022 | |
| Shockwave Medical, INC | $119.05 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $110.72 | 2021-2022 | |
| Vital Connect, INC | $103.09 | 2023-2025 | Vitalpatch Rtm |
| Edwards Lifesciences Corporation | $64.91 | 2021 | |
| Pfizer INC. | $63.54 | 2022 | |
| Amarin Pharma, INC. | $60.08 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.37 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.44 | 2021 | |
| Heartflow, INC. | $31.06 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $30.10 | 2024 | Evkeeza, Praluent |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $29.27 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $19.48 | 2022 | |
| Boston Scientific Corporation | $13.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Mani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.